company background image
2196 logo

Shanghai Fosun Pharmaceutical (Group) SHSC:2196 Stock Report

Last Price

HK$14.06

Market Cap

HK$65.0b

7D

1.6%

1Y

-17.3%

Updated

27 Dec, 2024

Data

Company Financials +

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSC:2196 Stock Report

Market Cap: HK$65.0b

2196 Stock Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details

2196 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings are forecast to grow 29.08% per year

Risk Analysis

Profit margins (5.1%) are lower than last year (8.3%)

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

Sino Biopharmaceutical

SEHK:1177

HK$58.8b

CSPC Pharmaceutical Group

SEHK:1093

HK$55.7b

Hansoh Pharmaceutical Group

SEHK:3692

HK$105.6b

China Resources Pharmaceutical Group

SEHK:3320

HK$34.9b

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥14.06
52 Week HighCN¥19.50
52 Week LowCN¥11.32
Beta0.72
1 Month Change-2.50%
3 Month Change-1.40%
1 Year Change-17.29%
3 Year Change-59.07%
5 Year Change-40.80%
Change since IPO-46.94%

Recent News & Updates

Recent updates

Shareholder Returns

2196HK PharmaceuticalsHK Market
7D1.6%0.8%1.9%
1Y-17.3%-6.5%18.1%

Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -6.5% over the past year.

Return vs Market: 2196 underperformed the Hong Kong Market which returned 18.1% over the past year.

Price Volatility

Is 2196's price volatile compared to industry and market?
2196 volatility
2196 Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement8.6%
10% most volatile stocks in HK Market18.7%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 2196 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2196's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199439,309Deyong Wenwww.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
2196 fundamental statistics
Market capHK$64.99b
Earnings (TTM)HK$2.25b
Revenue (TTM)HK$44.25b

32.1x

P/E Ratio

1.6x

P/S Ratio

Is 2196 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2196 income statement (TTM)
RevenueCN¥41.61b
Cost of RevenueCN¥21.83b
Gross ProfitCN¥19.78b
Other ExpensesCN¥17.67b
EarningsCN¥2.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)0.80
Gross Margin47.55%
Net Profit Margin5.08%
Debt/Equity Ratio55.0%

How did 2196 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

34%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 17:58
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Yang HuangBofA Global Research